A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
- 03 May 2010 Results were presented at the American Society of Hypertension, Inc. 25th Annual Scientific Meeting, according to a Takeda Global Research and Development Center media release.
- 03 May 2010 Primary endpoint 'Systolic blood pressure' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History